Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


138

projects in our pipeline

1

new molecular entity approval in last quarter

11

new molecular entities in our late-stage pipeline


Phase III/Reg.* refers to assets that are in Phase III or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Filter By:

Oncology (as at 9 November 2017)

Phase 1

Phase 1

  • AZD0156 solid tumours
  • AZD2811 solid tumours
  • AZD4635 solid tumours
  • AZD4785 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • AZD9496 ER+ breast cancer
  • Imfinzi + AZD1775 solid tumours
  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + MEDI0562 solid tumours
  • Imfinzi + MEDI9197 solid tumours
  • Imfinzi + MEDI9447 solid tumours
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi or Imfinzi + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + Vidaza myelodysplastic syndrome
  • Lynparza + AZD1775 solid tumours
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3726 prostate cancer
  • MEDI4276 solid tumours
  • MEDI5083 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • AZD1775 solid tumours
  • AZD1775 + chemotherapy ovarian cancer
  • AZD4547 solid tumours
  • AZD5363 breast cancer
  • Imfinzi solid tumours
  • Imfinzi + AZD5069 pancreatic ductal adenocarcinoma
  • Imfinzi + AZD5069 Imfinzi + AZD9150 head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + tremelimumab hepatocellular carcinoma (liver cancer)
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + AZD6738 gastric cancer
  • Lynparza + Imfinzi MEDIOLA solid tumors
  • Lynparza + cediranib CONCERTO recurrent platinum resistant ovarian cancer
  • MEDI-573 metastatic breast cancer
  • Tagrisso BLOOM CNS metastases in advanced EGFRm non-small cell lung cancer
  • Tagrisso + or selumetinib or savolitinib) TATTON advanced EGFRm non-small cell lung cancer
  • vistusertib solid tumours

Phase 3

Phase 3

  • Calquence (acalabrutinib) B-cell malignancy
  • Calquence (acalabrutinib) 1st line chronic lymphocytic leukaemia
  • Calquence (acalabrutinib) relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence (acalabrutinib) 1st-line mantle cell lymphoma
  • Imfinzi PACIFIC stage III NSCLC
  • Imfinzi + tremelimumab ARCTIC 3rd-line non-small cell lung cancer
  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + chemotherapy POSEIDON 1st-line non-small cell lung cancer
  • moxetumomab pasudotox PLAIT hairy cell leukaemia
  • savolitinib SAVOIR papillary renal cell carcinoma
  • selumetinib ASTRA differentiated thyroid cancer

LCM Projects

LCM Projects

  • Faslodex FALCON 1st-line hormone receptor +ve advanced breast cancer
  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Tagrisso (AZD9291) ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso (AZD9291) FLAURA 1st-line advanced EGFRm non-small cell lung cancer

Cardiovascular and Metabolic Diseases (as at 9 November 2017)

Phase 1

Phase 1

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular
  • MEDI5884 cardiovascular

Phase 2

Phase 2

  • MEDI0382 type-2 diabetes
  • MEDI6012 cardiovascular
  • verinurad chronic kidney disease

Phase 3

Phase 3

  • Epanova severe hypertriglyceridaemia
  • ZS-9 (sodium-zirconium cyclosilicate) hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end stage renal disease

LCM Projects

LCM Projects

  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with type-2 diabetes and coronary artery disease without a previous history of myocardial infarction or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon BCise weekly autoinjector type-2 diabetes
  • Epanova STRENGTH cardiovascular outcomes study in statin-treated patients at high cardiovascular risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Farxiga/Forxiga worsening heart failure or cardiovascular death in patients with chronic heart failure
  • Farxiga/Forxiga renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga type-1 diabetes
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Kombiglyze XR/Komboglyze type-2 diabetes
  • Qtern type-2 diabetes
  • Xigduo XR/Xigduo type-2 diabetes
  • saxagliptin/dapagliflozin metformin type-2 diabetes

Respiratory (as at 9 November 2017)

Phase 1

Phase 1

  • AZD0284 psoriasis/respiratory
  • AZD5634 cystic fibrosis
  • AZD7594 + abediterol asthma/chronic obstructive pulmonary disease
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • AZD9898 asthma
  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • AZD1419 asthma
  • AZD7594 asthma/chronic obstructive pulmonary disease
  • AZD8871 chronic obstructive pulmonary disease
  • PT010 asthma
  • abediterol asthma/chronic obstructive pulmonary disease
  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • Bevespi Aerosphere PINNACLE chronic obstructive pulmonary disease
  • PT010 chronic obstructive pulmonary disease
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA chronic obstructive pulmonary disease
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Other (as at 9 November 2017)

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • MEDI9314 atopic dermatitis

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Pseudomonas aeruginosa pneumonia
  • MEDI4893 prevention of nosocomial Staphylococcus aureus pneumonia
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus
  • lanabecestat AMARANTH + extension, DAYBREAK-ALZ Alzheimer's disease

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)

Terminations

  • AZD9150 haematological malignancies
  • MEDI8111 trauma/bleeding